-
Mashup Score: 0CABINET: Cabozantinib Preserves Quality of Life in Patients With NETs | GI Oncology Now - 2 day(s) ago
Cabozantinib was found to improve progression-free survival in patients with advanced extra-pancreatic neuroendocrine tumors or pancreatic NET.
Source: www.gioncologynow.comCategories: General Medicine NewsTweet
-
Mashup Score: 1
Professor Tie discusses DYNAMIC-III, a trial using ctDNA to guide chemo escalation in stage III colon cancer.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🎥 Dr. @JeanneTie explores the outcomes of the randomized phase II/III DYNAMIC-III trial, which evaluated ctDNA-guided chemotherapy escalation in patients with stage III #coloncancer, in a new interview: https://t.co/aj89lQN9Pg https://t.co/naZVJL41Vg
-
-
Mashup Score: 0Gemcitabine Plus Cisplatin Boosts OS, Resection Rates for Biliary Tract Cancer | GI Oncology Now - 3 day(s) ago
A final analysis of the phase 3 GAIN trial has provided new insight into the efficacy of neoadjuvant/perioperative gemcitabine with cisplatin.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🔎 A final analysis of the phase 3 GAIN trial presented at #ASCO25 has pointed to the efficacy of neoadjuvant/perioperative #gemcitabine with #cisplatin. 👉 The combination boosted OS and R0 resection rates in patients with biliary tract cancer: https://t.co/xe9FZsqYjF
-
-
Mashup Score: 4HERIZON-BTC-01 vs a Real-World Control Arm: Comparing Zanidatamab With Chemotherapy for BTC | GI Oncology Now - 5 day(s) ago
Dr. Richard Kim discusses survival outcomes of zanidatamab compared to chemotherapy in patients with previously treated HER2+ biliary tract cancer at the 2025 ASCO Annual Meeting.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
📺 Dr. Richard Kim of @MoffittNews gives an overview of a study that determined the survival outcomes of #zanidatamab compared to chemotherapy in patients with previously treated HER2-positive biliary tract cancer: https://t.co/apF821VAuS https://t.co/kuk6ZEsWXj
-
-
Mashup Score: 1
Dr. Reni breaks a randomized phase III trial of pre-operative chemotherapy with mFOLFIRINOX or PAXG for stage I-III PDAC.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
💊 Dr. Michele Reni of Oncology Scientific Institute San Raffaele breaks down the CASSANDRA study, which explored the efficacy of pre-operative #chemotherapy with mFOLFIRINOX or #PAXG for stage I-III pancreatic ductal adenocarcinoma: https://t.co/RWxY8S42gL https://t.co/boXQVgFzVb
-
-
Mashup Score: 0Binimetinib Plus Imatinib: 10-Year Follow-Up Shows Benefit of Combination for Treatment-Naïve GISTs | GI Oncology Now - 10 day(s) ago
Long-term results support the durable efficacy of binimetinib plus imatinib in treatment-naïve advanced GIST.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
💊 Recent 10-year follow-up data presented at #ASCO25 supports the durable efficacy of #binimetinib plus #imatinib in treatment-naïve advanced #GIST: https://t.co/2BtZvLqTCU 👉 This update underscores the need for comparative frontline studies against imatinib monotherapy.
-
-
Mashup Score: 9
Dina Ioffe, MD, Fox Chase Cancer Center, talks about the use of immunotherapy in the neoadjuvant or adjuvant setting.
Source: www.gioncologynow.comCategories: General Medicine NewsTweet-
In this video, Fox Chase's Dina Ioffe, MD, discusses using immunotherapy in the neoadjuvant, adjuvant, and other settings to treat patients with advanced hepatocellular carcinoma (HCC): https://t.co/EEP4hBLmlM
-
-
Mashup Score: 0
The Claudin18.2 antibody-drug conjugate IBI343 is well tolerated and shows encouraging efficacy in patients with PDAC.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
👉 According to data presented at #ASCO25, the Claudin18.2 antibody-drug conjugate IBI343 is well tolerated and continues to show encouraging efficacy in patients with #pancreatic ductal adenocarcinoma: https://t.co/STwYflN0xC
-
-
Mashup Score: 0
Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
📺 Dr. Zev Wainberg of @UCLAHealth details the practice-changing implications of the MATTERHORN study's EFS data in a new interview: https://t.co/z2g0N4KaYC 👉 MATTERHORN examined the efficacy of a #durvalumab combination treatment in for resectable gastric/GEJ cancer. https://t.co/Xnw7MqegPw
-
-
Mashup Score: 0
The ATOMIC trial showed that adding atezo to mFOLFOX6 significantly improves DFS in stage III colon cancer and dMMR.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🔎 The phase 3 ATOMIC trial has demonstrated that adding #atezolizumab to standard adjuvant mFOLFOX6 chemotherapy can significantly improve disease-free survival in patients with stage 3 #coloncancer: https://t.co/OXRbNwj7Vh
-
💊 #Cabozantinib was found to improve PFS in patients with pancreatic NETs, with new findings presented at the 2025 ASCO Annual Meeting showing that the treatment maintained health-related quality of life: https://t.co/kgWCWzfPcT